Education
About Us
Working with TipRanks
Follow Us
Revelation Biosciences Inc. (REVB)
:REVB
REVB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $168.00
Previous CloseN/A
Volume326.26K
Average Volume (3M)258.48K
Market Cap
$3.97M
Enterprise Value-$1.15M
Total Cash (Recent Filing)$3.70M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 08, 2025EPS Estimate
-16.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.33
Shares Outstanding1,534,599
10 Day Avg. Volume223,304
30 Day Avg. Volume258,484
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.29
Enterprise Value/Revenue-42.65
Enterprise Value/Gross Profit140.61
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$20.00Price Target Upside672.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences Inc.’s price range in the past 12 months?
Revelation Biosciences Inc. lowest stock price was $2.10 and its highest was $168.00 in the past 12 months.
What is Revelation Biosciences Inc.’s market cap?
Revelation Biosciences Inc.’s market cap is $3.97M.
When is Revelation Biosciences Inc.’s upcoming earnings report date?
Revelation Biosciences Inc.’s upcoming earnings report date is Aug 08, 2025 which is today.
How were Revelation Biosciences Inc.’s earnings last quarter?
Revelation Biosciences Inc. released its earnings results on May 08, 2025. The company reported -$6.33 earnings per share for the quarter, beating the consensus estimate of -$20.64 by $14.31.
Is Revelation Biosciences Inc. overvalued?
According to Wall Street analysts Revelation Biosciences Inc.’s price is currently Undervalued.
Does Revelation Biosciences Inc. pay dividends?
Revelation Biosciences Inc. does not currently pay dividends.
What is Revelation Biosciences Inc.’s EPS estimate?
Revelation Biosciences Inc.’s EPS estimate is -16.38.
How many shares outstanding does Revelation Biosciences Inc. have?
Revelation Biosciences Inc. has 1,534,599 shares outstanding.
What happened to Revelation Biosciences Inc.’s price movement after its last earnings report?
Revelation Biosciences Inc. reported an EPS of -$6.33 in its last earnings report, beating expectations of -$20.64. Following the earnings report the stock price went up 2.583%.
Which hedge fund is a major shareholder of Revelation Biosciences Inc.?
Currently, no hedge funds are holding shares in REVB
Company Description
Revelation Biosciences Inc.
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Technical Analysis
VivoSim Labs
―
Aptevo Therapeutics
―
Enveric Biosciences
―
Ensysce Biosciences
―
Tao Synergies
―
Ownership Overview
3.01% Insiders
0.06% Mutual Funds
0.51% Other Institutional Investors
96.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---